Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.16 USD
+0.01 (0.87%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.15 -0.01 (-0.86%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 33% (84 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 3.00 | 1.58 | 9.99 |
Current Quarter Estimate | -0.08 | -1.06 | 61.00 |
Year Ago Quarter Estimate | -0.41 | -0.06 | 54.84 |
Next Quarter Estimate | -0.15 | -1.85 | 63.00 |
Next Year Estimate | -0.58 | 12.67 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 58.06 | 20.70 | 15.67 |
Next Year | 10.77 | 16.30 | 11.34 |
Last 5 Years | NA | 7.80 | 8.10 |
Next 5 Years | NA | 20.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -1.82 |
Price/Book (MRQ) | 0.61 | 1.59 |
Price/Cash Flow (MRFY) | NA | 9.47 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -183.28% | -61.35% |
Return on Equity (TTM) | -53.18% | -58.93% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.